Robert Zimmerman, MD
Endocrinology, Diabetes & Metabolism · Cleveland, OHNPI 1689764706
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Xeris Pharmaceuticals, Inc. accounts for 75.3% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2023 at $14,693 and has fallen 59.5% since, to $5,949 in 2025. Among endocrinology, diabetes & metabolism clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 193 payments — averaging $233.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Xeris Pharmaceuticals, Inc.$34K
- Lifescan, Inc.$5K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Novo Nordisk$1K
- Abbott$619
- Averitas Pharma Inc.$484
- plus $2K from 21 others
What the payments were for
- Consulting fees$17,67939%
- Speaking & faculty fees$21,05047%
- Travel & lodging$3281%
- Food & beverage$5,50312%
- Education$4821%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | 52 | $33,901 |
| Lifescan, Inc. | 3 | $4,810 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $2,000 |
| Novo Nordisk | 32 | $1,020 |
| Abbott | 30 | $619 |
| Averitas Pharma Inc. | 8 | $484 |
| Sanofi-aventis U.S. LLC | 11 | $403 |
| Corcept Therapeutics | 9 | $376 |
| Lilly USA, LLC | 8 | $204 |
| AstraZeneca | 8 | $182 |
| Johnson & Johnson | 6 | $165 |
| Tandem Diabetes Care, Inc. | 2 | $142 |
| Amryt Pharma Holdings Ltd | 3 | $104 |
| Boehringer Ingelheim | 3 | $97 |
| Merck | 3 | $96 |
| Bayer | 1 | $91 |
| Dexcom, Inc. | 2 | $56 |
| Recordati_rare_diseases_inc. | 2 | $52 |
| GSK | 1 | $46 |
| Gilead | 1 | $33 |
| Amarin Pharma, Inc. | 1 | $32 |
| Janssen Scientific Affairs, LLC | 1 | $28 |
| Novartis | 1 | $26 |
| EUSA Pharma (US) LLC | 1 | $20 |
| Aytu Biopharma, Inc. | 1 | $19 |
| GRT US Holding, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GVOKE HYPOPEN$30,834
- OneTouch$4,725
- GVOKE PFS$2,007
- CYCLOSET$2,000
- Qutenza$338
- t:slim X2 insulin pump$121
- Korlym$119
- SOLIQUA 100/33$118
- RYBELSUS$107
How this compares
$45,041 in reported general payments places this provider in the 90th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 241 | $285,187 |
| OzempicSemaglutide | 221 | $276,918 |
| JardianceEmpagliflozin | 184 | $187,189 |
| TrulicityDulaglutide | 118 | $149,844 |
| JanuviaSitagliptin Phosphate | 47 | $52,239 |
| Humalog Kwikpen U-200Insulin Lispro | 24 | $50,758 |
| FarxigaDapagliflozin Propanediol | 23 | $36,839 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 22 | $23,822 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $19,913 |
| Tresiba Flextouch U-100Insulin Degludec | 28 | $18,791 |
| Humalog Kwikpen U-100Insulin Lispro | 57 | $15,291 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 22 | $14,523 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 122 | $13,560 |
| Novolog FlexpenInsulin Aspart | 60 | $10,752 |
| Gvoke Hypopen 2-PackGlucagon | 16 | $9,882 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $204 | $446,613416 claims |
| Novo NordiskOzempic, Novolog | $1,020 | $285,549237 claims |
| Boehringer IngelheimJardiance | $97 | $187,189184 claims |
| MerckJanuvia | $96 | $52,23947 claims |
| AstraZenecaFarxiga | $182 | $36,83923 claims |
| Sanofi-aventis U.S. LLCLantus | $403 | $3,43622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Cleveland
- Kevin PantaloneCleveland$1.2M
- Allan KennedyCleveland$245K
- Adi MehtaCleveland$120K
- Amir HamrahianCleveland$59K
- Bartolome BurgueraCleveland$52K
- Christian NasrCleveland$46K
- Mario SkugorCleveland$45K
- Bahauddin ArafahCleveland$25K
- Divya Yogi-MorrenCleveland$24K
- Vinni MakinCleveland$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.